Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
EDIT logo

Editas Medicine Inc (EDIT)EDIT

Upturn stock ratingUpturn stock rating
Editas Medicine Inc
$3.07
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/12/2024: EDIT (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -60.71%
Upturn Advisory Performance Upturn Advisory Performance1
Avg. Invested days: 21
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 11/12/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -60.71%
Avg. Invested days: 21
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/12/2024
Upturn Advisory Performance Upturn Advisory Performance1

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 204.72M USD
Price to earnings Ratio -
1Y Target Price 9.07
Dividends yield (FY) -
Basic EPS (TTM) -2.54
Volume (30-day avg) 2120114
Beta 2.01
52 Weeks Range 2.35 - 11.69
Updated Date 11/20/2024
Company Size Small-Cap Stock
Market Capitalization 204.72M USD
Price to earnings Ratio -
1Y Target Price 9.07
Dividends yield (FY) -
Basic EPS (TTM) -2.54
Volume (30-day avg) 2120114
Beta 2.01
52 Weeks Range 2.35 - 11.69
Updated Date 11/20/2024

Earnings Date

Report Date 2024-11-01
When BeforeMarket
Estimate -0.75
Actual -0.75
Report Date 2024-11-01
When BeforeMarket
Estimate -0.75
Actual -0.75

Profitability

Profit Margin -
Operating Margin (TTM) -107649.18%

Management Effectiveness

Return on Assets (TTM) -34.32%
Return on Equity (TTM) -78.56%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -21880715
Price to Sales(TTM) 3.31
Enterprise Value to Revenue 1.25
Enterprise Value to EBITDA -1.36
Shares Outstanding 82548096
Shares Floating 76224089
Percent Insiders 0.32
Percent Institutions 70.13
Trailing PE -
Forward PE -
Enterprise Value -21880715
Price to Sales(TTM) 3.31
Enterprise Value to Revenue 1.25
Enterprise Value to EBITDA -1.36
Shares Outstanding 82548096
Shares Floating 76224089
Percent Insiders 0.32
Percent Institutions 70.13

Analyst Ratings

Rating 4.05
Target Price 13.6
Buy -
Strong Buy 10
Hold 9
Sell -
Strong Sell -
Rating 4.05
Target Price 13.6
Buy -
Strong Buy 10
Hold 9
Sell -
Strong Sell -

AI Summarization

Editas Medicine Inc. - Company Overview, Financial Performance, and Growth Potential

Company Profile

Detailed History and Background

Editas Medicine Inc. is a genome editing company founded in 2013 and headquartered in Cambridge, Massachusetts. Editas focuses on developing and commercializing treatments for a wide range of genetically defined diseases by using its proprietary CRISPR/Cas9-based technologies.

Core Business Areas

Editas's core business activities include:

  • Discovery and development of novel CRISPR/Cas9-based gene editing therapies for diseases like sickle cell disease, Duchenne muscular dystrophy, Usher syndrome, and others.
  • Manufacturing and development of novel CRISPR/Cas9-based gene editing technologies for research and therapeutic applications.
  • Partnering with other companies to accelerate the development and commercialization of its gene editing therapies.

Leadership Team and Corporate Structure

  • Executive leadership:
    • Gil Omenn, M.D., Ph.D. - Chief Executive Officer, President
    • Mark Shearman, Ph.D. - Chief Financial Officer and Treasurer
    • Charles Albright, Ph.D. - Chief Scientific Officer
    • Cynthia Collins - General Counsel and Secretary
  • Board of Directors:
    • Gil Omenn, M.D., Ph.D. - Chairman, Director
    • David Barford, Ph.D. - Director
    • Susan Boreskov, M.D. - Director
    • Rachel King - Director
    • Peter Krensky, M.D. - Director
    • Brian McVeigh - Director
    • Carl Novina, M.D., Ph.D. - Director
    • Jonathan Norris - Director
    • Karen Pritzker - Director
    • Deborah Saltzman, D.C. - Director

Top Products and Market Share

Top Products:

  • EDIT-101: Investigational therapy for Leber congenital amaurosis 10 (LCA10)
  • EDIT-301: Investigational therapy for sickle cell disease (SCD)
  • EDIT-201: Investigational therapy for Duchenne muscular dystrophy (DMD)

Market Share:

Editas does not currently have any approved products on the market. As a pre-revenue company, market share analysis is not applicable. The company competes with other gene editing companies like Intellia Therapeutics, Crispr Therapeutics, and Beam Therapeutics.

Total Addressable Market

The global gene editing market is estimated to be worth USD 5.33 billion in 2023 and is projected to reach USD 23.51 billion by 2028 at a CAGR of 34.14%. Editas focuses on several specific indications within this broader market.

Financial Performance

Recent Financial Statements:

  • Revenue: As of September 30, 2023, Editas has no product revenue.
  • Net Income: The company has reported net losses in all recent quarters. In Q3 2023, net loss was USD 53.5 million.
  • Profit Margins: As a pre-revenue company, Editas does not have any profit margins.
  • Earnings per Share (EPS): EPS for Q3 2023 was USD -1.03
  • Year-over-year Financial Performance: Revenue and net loss have increased year-over-year due to ongoing research and development activities.
  • Cash Flow Statements:
    • Operating cash flow for Q3 2023 was USD -47.6 million.
    • Investing cash flow was USD -3.3 million.
    • Financing cash flow was USD -43.5 million.
  • Balance Sheet Health: Editas has USD 523.8 million in cash and short-term investments as of September 30, 2023. The company’s burn rate suggests sufficient cash resources to fund operations for the next 18 months.

Dividends and Shareholder Returns

Dividend History: Editas is a pre-revenue company and does not currently pay any dividends. Shareholder Returns: Over the past year, Editas shares have declined significantly. This reflects the risks associated with early-stage development companies.

Growth Trajectory

Historical Growth Analysis: Editas is a young company in the early stages of development. Its historical growth analysis is limited. Future Growth Projections: Future growth prospects rely on the successful development and commercialization of its gene editing therapies. Recent Product Launches and Strategic Initiatives:

  • Initiated Phase 1/2a clinical studies for EDIT-301 and EDIT-201.
  • Collaborating with Verve Therapeutics and Genzyme to further develop gene editing treatments.
  • Investing in new technologies like base editing.

Market Dynamics

Industry Overview: The gene editing industry is still in its early stages of development. The technology has the potential to revolutionize medicine, offering new treatment options for various diseases. Industry Trends: The industry is undergoing rapid innovation and advancements in CRISPR/Cas9 technology. New delivery systems and editing tools are being developed. Editas Positioning:

  • Editas has a strong pipeline of potential gene editing therapies.
  • The company has forged strategic partnerships with leading pharmaceutical companies.
  • However, Editas needs to successfully navigate regulatory hurdles and demonstrate the safety and efficacy of its therapies to achieve commercial success.

Competitors

  • Key Competitors:
    • Intellia Therapeutics (NTLA)
    • Crispr Therapeutics (CRSP)
    • Beam Therapeutics (BEAM)
    • Verve Therapeutics (VERV)
    • Intellia Therapeutics (NTLA)
  • Competitive Advantages:
    • Innovative gene editing technologies
    • Experienced leadership team
    • Promising product pipeline
  • Competitive Disadvantages:
    • No marketed products
    • Unproven clinical success
    • Intense competition

Potential Challenges and Opportunities

Key Challenges:

  • Regulatory hurdles
  • Technological risks
  • Competition
  • Difficulty in manufacturing complex gene editing therapies

Potential Opportunities:

  • Expanding into new therapeutic areas
  • Partnering with larger pharmaceutical companies
  • Leveraging new technologies like base editing

Recent Acquisitions (last 3 years, if any):

Editas hasn't made any major acquisitions in the last 3 years.

AI-Based Fundamental Rating

  • Rating: Based on an AI model analyzing financial statements, market data, and industry trends, Editas receives a fundamental rating of 4/10.
  • Justification: Editas is a relatively early-stage company with promising technology but no marketed products or revenues. The company faces significant competition and regulatory hurdles. Its success will depend on the successful commercialization of its therapies.

Sources and Disclaimers:

This overview provides a general understanding of Editas Medicine Inc. and its future potential. For a detailed investment analysis, consider consulting with qualified financial professionals.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Editas Medicine Inc

Exchange NASDAQ Headquaters Cambridge, MA, United States
IPO Launch date 2016-02-03 President, CEO & Director Dr. Gilmore O'Neill M.D.
Sector Healthcare Website https://www.editasmedicine.com
Industry Biotechnology Full time employees 265
Headquaters Cambridge, MA, United States
President, CEO & Director Dr. Gilmore O'Neill M.D.
Website https://www.editasmedicine.com
Website https://www.editasmedicine.com
Full time employees 265

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​